Sarepta Therapeutics, Inc. SRPT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-2.78
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.9B | -$713.4M | — | -$307.5M | $1.1B |
| 2024 | $1.8B | $235.2M | — | -$342.7M | $1.5B |
| 2023 | $1.1B | -$536.0M | — | -$577.1M | $859.3M |
| 2022 | $933.0M | -$703.5M | — | -$356.2M | $384.9M |
| 2021 | $612.4M | -$418.8M | — | -$481.7M | $928.0M |
| 2020 | $540.1M | -$554.1M | — | $25.3M | $761.8M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.78 (distress)
- Working capital / assets 0.431
- Retained earnings / assets -1.456
- EBIT / assets -0.209
- Equity / liabilities 0.516
Source: SEC EDGAR filings · CIK 0000873303 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.